We'll focus this answer on the current brief.

Granules India said its subsidiary Granules Pharmaceuticals received USFDA tentative approval for generic amphetamine extended-release tablets for ADHD, with FDA-determined...

We'll focus this answer on the current brief.

The Delhi High Court asked Novo Nordisk to respond to Natco Pharma’s petition seeking revocation of Novo Nordisk’s semaglutide patent, which is set to expire in March.

We'll focus this answer on the current brief.

India's government banned all oral nimesulide formulations above 100 mg due to health risks, following ICMR's recommendation.

We'll focus this answer on the current brief.

India's obesity drug market has grown ten-fold in five years and is poised for further expansion with the entry of low-cost generics making treatments more accessible.

We'll focus this answer on the current brief.

FDA approved Wegovy pill for chronic weight loss, offering a daily oral alternative to weekly injections.

We'll focus this answer on the current brief.

FDA approval of oral Wegovy pill expands daily obesity treatment options and could enhance accessibility.

We'll focus this answer on the current brief.

Modulating macrophage metabolism to glycolysis raises oxidative stress and reduces TB bacteria drug tolerance, enabling shorter treatment in mice models.

We'll focus this answer on the current brief.

Kano Therapeutics produces circular single-stranded DNA to make gene therapies safer and more effective, aiming to enable broader treatment options.

We'll focus this answer on the current brief.

Hyderabad-based pharma companies are expanding in Andhra Pradesh's Kurnool due to Telangana abandoning its Pharma City and lack of available land.

We'll focus this answer on the current brief.

The FTSE 100 index closed at a record high of 9446 points, driven by AstraZeneca's surge and relief over potential tariff impacts on the pharma sector.

We'll focus this answer on the current brief.

Electroflow plans to produce lithium-iron-phosphate batteries at 40% lower costs than Chinese manufacturers, aiming to establish a domestic supply chain in the U.S.

We'll focus this answer on the current brief.

Regeneron's garetosmab shows promise in treating fibrodysplasia ossificans progressiva, a rare condition causing abnormal bone growth, with regulatory submissions planned.